Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era

Nithya Prasannan,Mari Thomas,Matthew Stubbs,John-Paul Westwood,Rens de Groot,Deepak Singh,Marie Scully

Blood（2023）

引用 2|浏览6

暂无评分

摘要

•Twenty-eight percent of patients treated with caplacizumab had persistent ADAMTS13 activity <30% within 30 + 28 days after PEX.•In patients with ADAMTS13 activity <10% on stopping caplacizumab, an ADAMTS13 antigen level <30% had higher risk of recurrence.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要